Objectives:

1. Understand utilization management (UM) criteria required for approval of PCSK9 inhibitors.

2. Guidance as to meeting UM so as to increase chance of success and reduce time for patient access to PCSK9 inhibitors.

3. Provide knowledge of additional LDL-C lowering agents in later stage clinical development which may impact their 
    management in the near future.

Session date: 
Friday, April 26, 2019 - 12:00pm to 1:00pm
Speaker Name: 
Evan Stein, MD, PhD
Location: 
UCMC
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.